USANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 773,228 shares of the company's stock after purchasing an additional 55,059 shares during the quarter. Dimensional Fund Advisors LP owned 4.06% of USANA Health Sciences worth $27,751,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of USANA Health Sciences during the 4th quarter worth approximately $28,000. Exchange Traded Concepts LLC lifted its position in shares of USANA Health Sciences by 11.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company's stock worth $308,000 after buying an additional 869 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of USANA Health Sciences by 4.8% in the 4th quarter. Franklin Resources Inc. now owns 22,070 shares of the company's stock valued at $792,000 after acquiring an additional 1,020 shares during the period. Principal Financial Group Inc. increased its holdings in shares of USANA Health Sciences by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after acquiring an additional 1,480 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of USANA Health Sciences by 35.4% in the 4th quarter. Wells Fargo & Company MN now owns 7,961 shares of the company's stock valued at $286,000 after acquiring an additional 2,082 shares during the period. Hedge funds and other institutional investors own 54.25% of the company's stock.

Wall Street Analysts Forecast Growth

USNA has been the topic of a number of recent research reports. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Sidoti cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, DA Davidson cut their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th.

USANA Health Sciences Stock Performance

NYSE:USNA traded up $0.34 during mid-day trading on Friday, hitting $29.52. 255,340 shares of the company's stock traded hands, compared to its average volume of 128,190. The firm's 50 day simple moving average is $27.34 and its 200 day simple moving average is $32.65. USANA Health Sciences, Inc. has a 1 year low of $23.10 and a 1 year high of $49.78. The company has a market cap of $549.75 million, a PE ratio of 10.43, a price-to-earnings-growth ratio of 0.93 and a beta of 0.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $249.54 million for the quarter, compared to analysts' expectations of $243.08 million. During the same period last year, the company earned $0.86 EPS. On average, research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at USANA Health Sciences

In related news, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now directly owns 15,716 shares of the company's stock, valued at $463,150.52. This represents a 24.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Joshua Foukas sold 5,732 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The disclosure for this sale can be found here. Insiders have sold a total of 16,594 shares of company stock valued at $520,384 over the last ninety days. Corporate insiders own 0.63% of the company's stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.